Chemical Component Summary

NameRETINOIC ACID
Identifiers(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
FormulaC20 H28 O2
Molecular Weight300.44
TypeNON-POLYMER
Isomeric SMILESCC1=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)(C)CCC1
InChIInChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
InChIKeySHGAZHPCJJPHSC-YCNIQYBTSA-N

Chemical Details

Formal Charge0
Atom Count50
Chiral Atom Count0
Bond Count50
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00755 
NameTretinoin
Groups
  • approved
  • investigational
  • nutraceutical
DescriptionTretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).
Synonyms
  • Vitamin A acid
  • all-trans-beta-Retinoic acid
  • Retinoic acid
  • Tretinoina
  • all-trans-Vitamin A1 acid
Brand Names
  • Clindamycin 1% / Niacinamide 4% / Tretinoin 0.05%
  • Hydrocortisone 0.5% / Hydroquinone 4% / Tretinoin 0.025%
  • OLIVIA QUIDO FIRM and FADE I
  • Vitamin A Acid 0.025% Gel
  • Niacinamide 4% / Tretinoin 0.025%
IndicationFor the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.
Categories
  • Alkenes
  • Anti-Acne Preparations
  • Anti-Acne Preparations for Topical Use
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
ATC-Code
  • D10AD51
  • L01XX14
  • D10AD01
CAS number302-79-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Retinoic acid receptor RXR-betaMSWAARPPFLPQRHAAGQCGPVGVRKEMHCGVASRWRRRRPWLDPAAAAA...unknownagonist
Retinoic acid receptor RXR-gammaMYGNYSHFMKFPAGYGGSPGHTGSTSMSPSAALSTGKPMDSHPSYTDTPV...unknownagonist
Retinoic acid receptor gammaMATNKERLFAAGALGPGSGYPGAGFPFAFPGALRGSPPFEMLSPSFRGLG...unknownagonist
Retinal dehydrogenase 1MSSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELC...unknown
Retinoic acid-induced protein 3MATTVPDGCRNGLKSKYYRLCDKAEAWGIVLETVATAGVVTSVAFMLTLP...unknown
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682